company background image
ENOV

Enovis NYSE:ENOV Stock Report

Last Price

US$63.85

Market Cap

US$3.4b

7D

-1.3%

1Y

-51.9%

Updated

25 May, 2022

Data

Company Financials +
ENOV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance1/6
Financial Health3/6
Dividends0/6

ENOV Stock Overview

Enovis Corporation operates as a medical technology company worldwide.

Enovis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enovis
Historical stock prices
Current Share PriceUS$63.85
52 Week HighUS$164.01
52 Week LowUS$59.15
Beta2.31
1 Month Change-5.15%
3 Month Change-49.49%
1 Year Change-51.86%
3 Year Change-16.60%
5 Year Change-47.53%
Change since IPO1.35%

Recent News & Updates

May 23

Enovis: Medtech Leftover Of Colfax With Some To Prove

Enovis has been the medtech segment which remained following the spin-off from Colfax. The standalone business has some to prove, as margins need a boost to create appeal here. I think that the valuations here are too demanding, preferring the welding ESAB business.

Shareholder Returns

ENOVUS Medical EquipmentUS Market
7D-1.3%1.4%1.0%
1Y-51.9%-15.8%-15.1%

Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned -16.7% over the past year.

Return vs Market: ENOV underperformed the US Market which returned -13.2% over the past year.

Price Volatility

Is ENOV's price volatile compared to industry and market?
ENOV volatility
ENOV Average Weekly Movement13.0%
Medical Equipment Industry Average Movement10.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: ENOV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ENOV's weekly volatility has increased from 7% to 13% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a16,200Matt Trerotolahttps://www.enovis.com

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.

Enovis Fundamentals Summary

How do Enovis's earnings and revenue compare to its market cap?
ENOV fundamental statistics
Market CapUS$3.45b
Earnings (TTM)US$85.63m
Revenue (TTM)US$4.00b

40.3x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENOV income statement (TTM)
RevenueUS$4.00b
Cost of RevenueUS$2.32b
Gross ProfitUS$1.68b
Other ExpensesUS$1.59b
EarningsUS$85.63m

Last Reported Earnings

Apr 01, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.58
Gross Margin41.97%
Net Profit Margin2.14%
Debt/Equity Ratio44.6%

How did ENOV perform over the long term?

See historical performance and comparison

Valuation

Is Enovis undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


40.29x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: ENOV ($63.85) is trading above our estimate of fair value ($41.51)

Significantly Below Fair Value: ENOV is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ENOV is poor value based on its Price-To-Earnings Ratio (40.3x) compared to the US Medical Equipment industry average (35.2x).

PE vs Market: ENOV is poor value based on its Price-To-Earnings Ratio (40.3x) compared to the US market (14.9x).


Price to Earnings Growth Ratio

PEG Ratio: ENOV is poor value based on its PEG Ratio (13.4x)


Price to Book Ratio

PB vs Industry: ENOV is good value based on its Price-To-Book Ratio (0.7x) compared to the US Medical Equipment industry average (2.4x).


Future Growth

How is Enovis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


3.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENOV's forecast earnings growth (3% per year) is above the savings rate (1.9%).

Earnings vs Market: ENOV's earnings (3% per year) are forecast to grow slower than the US market (12.1% per year).

High Growth Earnings: ENOV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ENOV's revenue is expected to decline over the next 3 years (-24.8% per year).

High Growth Revenue: ENOV's revenue is forecast to decline over the next 3 years (-24.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENOV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Enovis performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ENOV has a large one-off loss of $99.2M impacting its April 1 2022 financial results.

Growing Profit Margin: ENOV's current net profit margins (2.1%) are lower than last year (2.5%).


Past Earnings Growth Analysis

Earnings Trend: ENOV's earnings have grown by 9.2% per year over the past 5 years.

Accelerating Growth: ENOV's earnings growth over the past year (7.8%) is below its 5-year average (9.2% per year).

Earnings vs Industry: ENOV earnings growth over the past year (7.8%) underperformed the Medical Equipment industry 16.1%.


Return on Equity

High ROE: ENOV's Return on Equity (1.9%) is considered low.


Financial Health

How is Enovis's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ENOV's short term assets ($2.3B) exceed its short term liabilities ($1.5B).

Long Term Liabilities: ENOV's short term assets ($2.3B) do not cover its long term liabilities ($2.4B).


Debt to Equity History and Analysis

Debt Level: ENOV's net debt to equity ratio (30.3%) is considered satisfactory.

Reducing Debt: ENOV's debt to equity ratio has increased from 39% to 44.6% over the past 5 years.

Debt Coverage: ENOV's debt is not well covered by operating cash flow (12.4%).

Interest Coverage: ENOV's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet


Dividend

What is Enovis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENOV's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ENOV has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Matt Trerotola (54 yo)

6.83yrs

Tenure

US$13,833,746

Compensation

Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD13.83M) is above average for companies of similar size in the US market ($USD6.91M).

Compensation vs Earnings: Matt's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: ENOV's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: ENOV's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ENOV insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.


Top Shareholders

Company Information

Enovis Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Enovis Corporation
  • Ticker: ENOV
  • Exchange: NYSE
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$3.450b
  • Shares outstanding: 54.03m
  • Website: https://www.enovis.com

Number of Employees


Location

  • Enovis Corporation
  • 2711 Centerville Road
  • Suite 400
  • Wilmington
  • Delaware
  • 19808
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2022/04/01
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.